Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2022-02-23 Annual Report
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Final Results
Annual Report Classification · 1% confidence The document is titled 'Final Results' for N4 Pharma PLC for the year ended 31 December 2021. It contains a comprehensive overview of company activities, operational highlights, a Chairman's report, and the Consolidated Statement of Comprehensive Income. While it is presented as an RNS announcement, it contains the full substantive financial results and management discussion for the fiscal year, fitting the definition of an Annual Report (10-K) in the context of UK-listed companies reporting final results. FY 2021
2022-02-23 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, time-sensitive operational announcement related to trading mechanisms. This type of general regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category, RNS (Regulatory News Service). The document length is short (1931 chars), but it is the primary announcement itself, not an announcement *about* another report.
2022-02-22 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and contains information related to the London Stock Exchange's trading mechanisms, specifically a 'Price Monitoring Extension' and an 'auction call period' extension. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement disseminated via the RNS system, which is not a specific financial report like 10-K, ER, or IR. Since it is a miscellaneous regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the appropriate fallback category is Regulatory Filings (RNS). The document length is short (1914 chars), but it is the primary content, not an announcement *about* another report.
2022-02-22 English
Second Price Monitoring Extn
Interest Rate Update/Notice Classification · 1% confidence The document is very short (1930 characters) and contains the header 'RNS Number : 1297A'. It discusses a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement distributed via the RNS system, rather than a specific financial report like an ER, IR, or 10-K. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or DLST), the most appropriate classification is the general Regulatory Filings category.
2022-01-31 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document explicitly mentions 'RNS Number', 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom', and ends with an RNS identifier ('PMEEANFFDEEAEEA'). The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, which is a type of regulatory market announcement. Given the explicit reference to RNS and the nature of the brief, non-financial report content, this fits best under the general Regulatory Filings category (RNS), as it is not a specific report like 10-K, ER, or IR, nor is it a report publication announcement (RPA) which typically announces the release of a different, larger document. It is a direct regulatory notice.
2022-01-31 English
Granting of Patents
Regulatory Filings Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 0490A' and contains language typical of regulatory news service announcements, such as 'This information is provided by RNS, the news service of the London Stock Exchange.' The content announces a specific corporate event: the granting of patents in the US and China related to the company's core technology (Nuvec®). This type of material announcement, which is not a full financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV), fits best under the general 'Regulatory Filings' category (RNS), which serves as a fallback for miscellaneous regulatory news releases that don't fit more specific categories like DIRS or CAP. Given the nature of the announcement (IP/Patent Grant), RNS is the most appropriate general classification.
2022-01-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.